GlassScriptPhysician profile
Amanda H Cook
NPI 1366527558
$2,882.04
in general payments reported to CMS, 2019-2025
21 companies · $440 in 2025
The $440 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $546 · 2020: $109 · 2021: $296 · 2022: $357 · 2023: $526 · 2024: $608 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,573.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $556.90 | 2019-2024 | Jornay Pm |
| Corium, LLC | $509.35 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $270.62 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $246.47 | 2021-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Tris Pharma INC | $233.15 | 2019-2023 | Dyanavel Xr |
| Sanofi Pasteur INC. | $214.60 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $161.33 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $129.94 | 2021-2022 | |
| Neos Therapeutics, LP | $106.15 | 2019-2020 | |
| Pfizer INC. | $82.22 | 2019-2025 | |
| Glaxosmithkline, LLC. | $66.58 | 2019-2023 | Pediarix, Bexsero |
| Regeneron Healthcare Solutions, INC. | $59.63 | 2024-2025 | Dupixent |
| Genentech USA, INC. | $51.36 | 2019 | |
| Seqirus USA INC | $34.52 | 2024-2025 | Flucelvax |
| Kaleo, INC. | $28.47 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $26.73 | 2019 | |
| Shire North American Group INC | $26.21 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $26.15 | 2023 | |
| Sobi, INC | $23.76 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.62 | 2023 | Flumist Quadrivalent |
| Adlon Therapeutics L.P. | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.